LX-086

News alerts, weekly reports and conference planners

Company:

Luoxin Pharma

Drug class:

PI3Kα inhibitor

Related drugs:

PIK3CA H1047R	Ovarian Cancer	PIK3CA H1047R	Ovarian Cancer	LX-086 Sensitive: D – Preclinical LX-086 Sensitive : D	LX-086 Sensitive: D – Preclinical LX-086 Sensitive : D
PIK3CA H1047R	HER2 Negative Breast Cancer	PIK3CA H1047R	HER2 Negative Breast Cancer	LX-086 Sensitive: D – Preclinical LX-086 Sensitive : D	LX-086 Sensitive: D – Preclinical LX-086 Sensitive : D
PIK3CA amplification	HER2 Positive Breast Cancer	PIK3CA amplification	HER2 Positive Breast Cancer	LX-086 Sensitive: D – Preclinical LX-086 Sensitive : D	LX-086 Sensitive: D – Preclinical LX-086 Sensitive : D

Associations
(3)